DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 20825/S-054
NDA 20919/S-041
NDA 21483/S-014

SUPPLEMENT APPROVAL

Pfizer Inc.
Attention: Mary Boylan-Bost
Director, US Regulatory Cluster Lead
235 East 42nd Street
New York, NY 10017

Dear Ms. Boylan-Bost:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received March 31, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Geodon (ziprasidone) 20 mg, 40 mg, 60 mg, and 80 mg Capsules (NDA 20825), Geodon (ziprasidone mesylate) 20 mg/ml injection (NDA 20919), and Geodon (ziprasidone hydrochloride) 10 mg/ml oral suspension (NDA 21483).

These supplemental new drug applications provide for revisions to the Warnings and Precautions and Patient Counseling Information sections of the product labeling to expand the Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) language to include text for other severe cutaneous adverse reactions.

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please email Simran Parihar, PharmD, Regulatory Health Project Manager, at simran.parihar@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
08/20/2015